Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07401277 · ClinicalTrials.gov registry record · Phase 1
Actinic Keratoses Treated With 5-fluorouracil Plus Aluminum
A Phase 1 study, sponsored by West Virginia University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT07401277 is a Phase 1 study that is actively recruiting participants, run by West Virginia University. The registered enrollment target is 32 participants.
The verdict
NCT07401277, a Phase 1 study, is actively recruiting participants, sponsored by West Virginia University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This study is looking at a new way to treat actinic keratoses, which are rough, scaly spots on the skin caused by long-term sun exposure. These spots are common in older adults and, if not treated, can sometimes develop into a type of skin cancer. Doctors often treat areas with many of these spots by using a prescription cream called 5-fluorouracil (5-FU), which helps remove damaged skin cells. This study is testing whether adding aluminum chloride hexahydrate, a medication commonly used to stop bleeding during skin procedures, can improve how well the cream works. People who take part in this study will receive one of two treatments applied to their skin: Standard treatment with 5% 5-fluorouracil cream, or A combination of 5% 5-fluorouracil cream plus 15% aluminum chloride hexahydrate cream The treatment will be applied for one week. A dermatologist will examine the treated skin areas, count the number of actinic keratoses, and take photographs before treatment begins, shortly after treatment ends, and again about eight weeks later. These visits help researchers compare how well each treatment reduces the number of skin spots over time. The goal of this study is to learn whether adding aluminum chloride hexahydrate to standard treatment helps reduce actinic keratoses more effectively than standard treatment alone.
Interventions
- DRUG 5% 5-fluorouracil (5-FU) powder
- DRUG 5% 5-fluorouracil (5-FU) powder PLUS 15% Aluminum Chloride Hexahydrate (ACH)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2026-02-06 |
| Est. Completion | 2027-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07401277
The ClinicalTrials.gov registry entry for NCT07401277 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is West Virginia University, which has 122 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 5% 5-fluorouracil (5-FU) powder is the first listed.
NCT07401277 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07401277 about?
NCT07401277 is a clinical study titled "Actinic Keratoses Treated With 5-fluorouracil Plus Aluminum". This study is looking at a new way to treat actinic keratoses, which are rough, scaly spots on the skin caused by long-term sun exposure. These spots are common in older adults and, if not treated, can sometimes develop into a type of skin cancer. Doctors often treat areas with many of these spots ...
What is the current status of trial NCT07401277?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2026-02-06. Estimated completion is 2027-08.
What interventions are being tested in trial NCT07401277?
The interventions under investigation include: 5% 5-fluorouracil (5-FU) powder (DRUG), 5% 5-fluorouracil (5-FU) powder PLUS 15% Aluminum Chloride Hexahydrate (ACH) (DRUG).
Who is sponsoring clinical trial NCT07401277?
This trial is sponsored by West Virginia University, which has 122 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.